Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

Frances D. Buckley, Claire Arnold, Dawn Brass, Mark Catherwood, Mary Frances McMullin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Downloads (Pure)


Polycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) 
This analysis of newly diagnosed JAK2 mutant PV patients (n = 50) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.

We found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.

Original languageEnglish
Number of pages4
JournalIrish Journal of Medical Science
Early online date08 Sep 2023
Publication statusEarly online date - 08 Sep 2023


  • Haematology
  • Myeloproliferative neoplasms
  • Polycythaemia

Cite this